PTC Therapeutics (NASDAQ:PTCT) Posts Earnings Results, Beats Expectations By $0.42 EPS

PTC Therapeutics (NASDAQ:PTCT) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.42, FiscalAI reports. The business had revenue of $272.55 million for the quarter, compared to analyst estimates of $218.80 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The business’s revenue for the quarter was up 43.5% compared to the same quarter last year. During the same quarter last year, the company earned $10.04 earnings per share.

Here are the key takeaways from PTC Therapeutics’ conference call:

• Record quarter with $273M total revenue and $226M net product revenue; management raised 2026 product revenue guidance to $750M–$850M and total revenue to $1.08B–$1.18B.
• Sephience launch accelerating—Q1 Sephience revenue was $125M (36% QoQ), U.S. starts averaging ~140/month, >90% of U.S. PKU centers have prescribed, and commercial roll‑out is planned in up to 30 countries by year‑end with payers covering >2/3 of the U.S. population.
• Positive 24‑month PIVOT‑HD interim results for votoplam: the 10 mg dose showed a ~52% slowing of disease progression vs a matched natural history cohort in Stage 2 and a favorable safety profile, supporting the Novartis‑led phase III INVEST‑HD (≈770 pts) now enrolling.
• Vatiquinone path forward agreed with FDA: an open‑label, natural‑history‑controlled 24‑month study (≈120 patients, age 7–21, primary mFARS) will be initiated to support NDA resubmission, which management says increases probability of success but requires additional data collection.
• Strong liquidity with $1.89B in cash, cash equivalents and marketable securities as of March 31, 2026, which management says supports ongoing R&D, the Sephience launch, and selective accretive business development.

PTC Therapeutics Trading Up 14.3%

NASDAQ PTCT traded up $9.20 during trading hours on Friday, reaching $73.69. The company’s stock had a trading volume of 5,836,355 shares, compared to its average volume of 1,252,004. PTC Therapeutics has a 52 week low of $43.17 and a 52 week high of $87.50. The stock has a market cap of $6.11 billion, a PE ratio of 9.52 and a beta of 0.53. The business has a 50-day simple moving average of $67.69 and a 200 day simple moving average of $72.07.

Insider Buying and Selling

In other PTC Therapeutics news, insider Neil Gregory Almstead sold 52,003 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $69.04, for a total value of $3,590,287.12. Following the completion of the sale, the insider directly owned 60,137 shares of the company’s stock, valued at approximately $4,151,858.48. This represents a 46.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephanie Okey sold 15,167 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $70.00, for a total transaction of $1,061,690.00. Following the transaction, the director owned 8,000 shares of the company’s stock, valued at approximately $560,000. This trade represents a 65.47% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 126,492 shares of company stock worth $8,634,621. 5.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. IFP Advisors Inc boosted its position in PTC Therapeutics by 68.1% during the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 310 shares during the period. Virtus Investment Advisers LLC raised its holdings in shares of PTC Therapeutics by 3.6% during the fourth quarter. Virtus Investment Advisers LLC now owns 9,033 shares of the biopharmaceutical company’s stock worth $686,000 after acquiring an additional 316 shares in the last quarter. UMB Bank n.a. purchased a new stake in shares of PTC Therapeutics during the fourth quarter worth $26,000. Mariner LLC boosted its position in PTC Therapeutics by 5.1% during the third quarter. Mariner LLC now owns 8,745 shares of the biopharmaceutical company’s stock valued at $537,000 after purchasing an additional 426 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in PTC Therapeutics by 96.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 921 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 452 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on PTCT shares. Cantor Fitzgerald restated an “overweight” rating on shares of PTC Therapeutics in a report on Friday, February 20th. Morgan Stanley reiterated an “overweight” rating and issued a $94.00 target price on shares of PTC Therapeutics in a research note on Friday. Truist Financial upgraded PTC Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Raymond James Financial began coverage on PTC Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $108.00 price target on the stock. Finally, Royal Bank Of Canada raised their price objective on PTC Therapeutics from $81.00 to $82.00 and gave the company a “sector perform” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $88.36.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported Q1 revenue of $273 million and EPS of -$0.03, beating Wall Street estimates on both the top and bottom line. Revenue was up 43.5% year over year, and the company said its updated results support a higher full-year 2026 outlook. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company raised FY 2026 revenue guidance to $1.1 billion-$1.2 billion, above the market’s prior expectation of about $1.0 billion, signaling stronger commercial momentum. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: Wells Fargo lifted its price target on PTCT from $86 to $95 and kept an Overweight rating, suggesting further upside if execution continues. Benzinga report on Wells Fargo price target increase
• Neutral Sentiment: Royal Bank of Canada raised its price target from $81 to $82 while maintaining a Sector Perform rating, indicating a more measured view than Wells Fargo despite still acknowledging some upside. Benzinga report on RBC price target increase
• Neutral Sentiment: Management also highlighted progress in its pipeline and programs, including Sephience launch growth and positive interim data for votoplam, which may support longer-term sentiment but is less immediately impactful than the earnings beat. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.